6533b82afe1ef96bd128c052

RESEARCH PRODUCT

Cyclosporine A + Glybenclamide. Effect on Glucose Metabolism: Preliminary Results

F. BiondiAntony GalioneF. VaccaroV. Hopps

subject

Blood levelDrugbusiness.industrymedicine.medical_treatmentmedia_common.quotation_subjectCarbohydrate metabolismPharmacologymedicine.diseaseHydropic degenerationImmunosuppressive drugHigh dosageMetabolic effectsmedicinebusinessmedia_common

description

Cyclosporine A (CsA) is an immunosuppressive drug which determines, at high dosage, glucose intolerance (1). Different drugs present a pharmacological interaction with CsA increasing or reducing its blood level (2). To investigate the role of Glybenclamide (HB419), a sulphonilureic oral antidiabetic drug of large use, on CsA glucose metabolic effect, we have administered CsA + HB419 in rats. The aim of our work is to evaluate if HB419 influences CsA blood levels and if it improves glucose tolerance.

yearjournalcountryeditionlanguage
1989-01-01
https://doi.org/10.1007/978-1-4613-0865-2_140